Spot Trading’s Alaunos Therapeutics TCRT Stock Holding History

Spot Trading’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$36K	Buy	+39	New	+$34.6K	﹤0.01%	2803
2017 Q1	–	Sell	-298	Closed	-$239K	–	3304
2016 Q4	$239K	Buy	+298	New	+$269K	0.01%	1824
2016 Q3	–	Sell	-2	Closed	-$2K	–	3503
2016 Q2	$2K	Sell	2 -1	-33%	-$1.09K	﹤0.01%	3208
2016 Q1	$4K	Sell	3 -69	-96%	-$70.6K	﹤0.01%	3262
2015 Q4	$90K	Buy	72 +5	+7%	+$8.27K	﹤0.01%	2853
2015 Q3	$90K	Sell	67 -141	-68%	-$233K	﹤0.01%	3095
2015 Q2	$374K	Sell	208 -8	-4%	-$12.4K	﹤0.01%	2305
2015 Q1	$349K	Buy	+216	New	+$320K	﹤0.01%	2382

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spot Trading's TCRT Position: Q3 2017 in Review

Spot Trading opened a new position in Alaunos Therapeutics (TCRT) in Q3 2017: 83 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2636 among its holdings. This is a return to the name: Spot Trading previously reported a position in TCRT as recently as Q4 2016.

Spot Trading first reported a position in TCRT in Q3 2014 and has held it in 11 quarters since. The position peaked at $109K in Q2 2016. 122 funds tracked by Wall St. Rank hold TCRT as of Q3 2017.

Spot Trading held 83 shares of Alaunos Therapeutics worth $76K as of Q3 2017.
Alaunos Therapeutics was a new Spot Trading position in Q3 2017.
Alaunos Therapeutics made up ﹤0.01% of Spot Trading's portfolio in Q3 2017, its #2636 holding.
Spot Trading first reported a position in Alaunos Therapeutics in Q3 2014 and has held it in 11 quarters since.
Spot Trading's Alaunos Therapeutics position peaked at $109K in Q2 2016.
122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.